A Nature Biomedical Engineering study engineered IL‑10 to target LDL particles and reported targeted delivery reduced vascular inflammation in preclinical atherosclerosis models. The approach concentrates anti‑inflammatory cytokine activity at plaque sites and lowered markers of arterial inflammation, suggesting a precision cytokine therapy strategy. The paper positions engineered cytokine targeting as a possible route to modulate chronic vascular inflammation while limiting systemic immunosuppression.